The HealthAlpha Podcast

Sushaant Bakhru

HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region.

Episodes

  1. Jun 29

    The Future of Metabolic Health: GLP-1, Longevity & Preventive Measures

    What happens when a doctor sees a healthcare problem so big she can't ignore it? In this episode, I sit down with Dr. Sue-Ann Toh, endocrinologist, researcher, and co-founder of Novi Health, who left the traditional path of medicine to tackle Asia's growing diabetes and metabolic health crisis head-on. From leading one of Singapore's largest Type 2 diabetes studies to building a preventive healthcare company backed by a Series A round, her journey is anything but conventional. We talk about why Asians develop diabetes at lower BMI levels, what most people misunderstand about GLP-1 weight loss drugs, the future of personalized longevity and healthspan, and how technology can help prevent chronic disease before it starts. If you've ever wondered whether healthcare should focus more on prevention than treatment, this conversation will challenge how you think about health, obesity, weight loss, and aging. IN THIS EPISODE 00:00 | Why Healthy Asians Get Diabetes So Early 01:13 | The Hidden Metabolic Risk Most Asians Miss 06:39 | Why Singapore Has One of the World's Biggest Diabetes Problems 09:14 | How to Spot Diabetes Risk Before Blood Tests Do 13:37 | The Real Goal: Living Longer Without Getting Sick 15:52 | Are GLP-1 Weight Loss Drugs Built for Asians? 19:06 | What Actually Happens When Real People Use GLP-1s 23:13 | Why Three Doctors Started Novi Health 25:29 | Why Healthcare Pays for Disease, Not Prevention 30:59 | Why Employee Health Impacts Productivity More Than You Think 32:22 | The Simple Program Helping People Improve Metabolic Health 36:04 | The Biggest Mistakes People Make With GLP-1 40:01 | How to Lose Fat Without Losing Muscle 43:06 | Can AI Predict Your Future Health? 47:09 | The Future of Personalized Preventive Healthcare 49:10 | From Doctor to Startup Founder: Sue-Ann's Journey 52:59 | Advice for HealthTech Founders ABOUT SUE-ANN TOH Dr Sue-Anne Toh is a Senior Consultant Endocrinologist with nearly 20 years of experience in internal medicine, diabetes, and metabolic health. Trained in Cambridge and the University of Pennsylvania, she specializes in diabetes, lipid disorders, and cardiovascular risk management. Dr Toh is also a clinician-scientist and educator with a strong focus on holistic, patient-centered care. ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    The Future of Metabolic Health: GLP-1, Longevity & Preventive Measures
  2. Jun 15

    The $Billion Opportunity Hidden in Existing Medicines

    What if the biggest opportunities in pharma aren't new drugs at all? In this episode, I sit down with Sreevatsa Natarajan, CEO of Revio Therapeutics, who has spent 25+ years developing medicines across companies like Vertex, Dr. Reddy’s, Glenmark, and more. We explore why many approved drugs are still "unfinished," how drug repurposing and drug reformulation can unlock massive value, and why he believes pharma innovation has overlooked a lucrative middle lane between generics and blockbuster drug discovery. From FDA orphan drug designation and the 505(b)(2) pathway to building an AI-powered biotech startup from India, Sreevatsa shares the lessons, risks, and opportunities that shaped his journey. If you're interested in healthcare innovation, biotech startups, pharmaceutical R&D, drug development, or healthtech investing, this conversation is packed with insights. IN THIS EPISODE 00:00 | Why Most Pharma Innovation Misses the Biggest Opportunity 01:10 | The Untapped Middle Lane Between Generics and New Drugs 02:55 | Why Drug Development Keeps Getting More Expensive 04:45 | Why Many Approved Drugs Are Still "Unfinished" 10:25 | Drug Repurposing vs Off-Label Use Explained 12:55 | The FDA Shortcut That Can Save Years 14:55 | How Better Drug Design Improves Patient Outcomes 19:25 | How Revio Therapeutics Uses AI to Find New Drug Opportunities 21:20 | The Framework Behind Choosing Winning Drug Projects 25:35 | Inside Revio’s Orphan Drug Success Story 28:35 | Why Rare Diseases Can Be Attractive Markets 30:50 | The Business Model Behind Drug Repurposing 32:05 | How Pharma Startups Build Defensible IP 34:00 | The Real Moats in Healthcare Innovation 35:20 | The Advantages of Building a Biotech Startup in India 37:40 | Why Healthcare Innovation Struggles to Get Funded 38:25 | The Investment Opportunity Most Pharma Investors Ignore 40:10 | The Biggest Mistake Healthcare Founders Make 42:45 | Why Vatsa Is Betting Big on Pharma's Middle Lane Sreevatsa Natarajan | Co-Founder, Chief Executive Officer Vatsa has over 25 years of experience in pharma product development and commercialization with contribution to 15 NDAs, 25+ INDs, and several marketed therapies. A serial entrepreneur and seasoned R&D leader, he brings deep expertise across global organizations including Vertex, PPD, Glenmark, DRL Aurigene, Sapien (a JV with Apollo Hospitals), and Rhizen. Vatsa excels at converting complex scientific ideas into viable businesses by building high-performance teams. Check them out at https://www.reviotx.com/  ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    The $Billion Opportunity Hidden in Existing Medicines
  3. Jun 8

    Inside the Science of Gut Health, Immunity & Longevity

    90% of serotonin is produced in the gut… and your microbiome could influence everything from immunity to Parkinson’s and even cancer risk. In this episode, Dr. Jeremy Lim, the co-founder of Amili, breaks down how the gut microbiome really works, why ultra-processed foods and antibiotics may be quietly damaging us, and how microbiome transplants are already changing lives. We also get into the science behind probiotics, fermented foods, the gut-brain axis, and why Asia needs its own microbiome research instead of relying on Western data. One of the most fascinating conversations I’ve had on health, longevity, and the future of medicine. IN THIS EPISODE  00:00 | Why Your Gut Controls More Than Digestion 03:12 | The Real Job of Your Immune System 04:56 | 3 Simple Foods Your Gut Loves 07:34 | What Processed Food Is Doing to You 09:43 | Why Asians Have Different Gut Bacteria 12:19 | Your Gut’s Link to Anxiety & Brain Health 15:42 | The Gut Bacteria Linked to Cancer 21:13 | Building Asia’s Biggest Microbiome Database 23:59 | Can Your Gut Predict Disease Early? 28:07 | The Science Behind Microbiome Transplants 35:29 | Probiotics vs Prebiotics Explained Properly 40:42 | The Billion-Dollar Opportunity in Gut Health 43:31 | How Jeremy Lost 12kg by Fixing His Gut ABOUT DR. JEREMY LIM MBBS, MPH, MRCS (Edinburgh), MMed (Surgery), FAMS, Dipl IB Lifestyle Medicine Advisor for Gut Microbiome Health, Longevity Clinic Malaysia Associate Professor Jeremy Lim is a medical doctor, triply trained and qualified in surgery, public health and lifestyle medicine. He is widely recognised for championing the role of the gut microbiome in metabolic health, immune function, and biological ageing, establishing microbiome science as a foundational pillar in preventive and personalised medicine. Trained across Singapore, the United Kingdom, and the United States, Assoc Prof Lim completed further training at Johns Hopkins Hospital and the Singapore General Hospital. His career spans senior healthcare leadership roles across government, the private sector, and industry, including Singapore’s Ministry of Health, SingHealth (Singapore’s largest healthcare group, where he oversaw research and education), and Oliver Wyman’s Health and Life Sciences practice in Asia, which he founded in 2013. Assoc Prof Lim has spent over a decade leading efforts to advance microbiome science for Asian populations, building one of the world’s largest multi-ethnic Asian gut microbiome databases and establishing a platform that enables pharmaceutical companies, clinicians, and researchers across more than 200 organisations to develop and validate microbiome-based insights specific to Asian populations, spanning colorectal cancer, metabolic disorders, healthy ageing, and immunotherapy. ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare #GutHealth #GutMicrobiome #Microbiome #Probiotics #Longevity #HealthPodcast #FMT #Biohacking

    Inside the Science of Gut Health, Immunity & Longevity
  4. Jun 1

    Asia’s Growing Strength in CDMOs

    I didn’t expect a conversation about CDMOs to sound this much like high-stakes strategy, global politics, and biotech survival. In this episode, I sit down with Nick Wigdahl, former Roche leader and now founder of Pharmagro, to unpack how pharmaceutical manufacturing actually works behind the scenes, why companies like Samsung Biologics and WuXi became global giants, and how India, China, and Korea are reshaping the future of biotech manufacturing. We get into biologics, cell and gene therapy, antibody drug conjugates (ADCs), pharma supply chains, private equity in healthcare, the US BIOSECURE Act, and why AI in pharma manufacturing is far more complicated than most people think. Nick also shares what he learned inside Roche, why CDMOs are becoming one of the most important parts of the pharmaceutical industry, and how Asian biotech is quietly becoming impossible to ignore. If you want to understand where the global biopharma industry is headed next, this episode connects the dots. IN THIS EPISODE 00:00 | The Invisible Industry Behind Every Medicine 01:16 | Why Big Pharma Depends on CDMOs 03:40 | How Roche, Pfizer & Biotechs Use CDMOs Differently 07:31 | Why Asia Is Becoming Biopharma’s Powerhouse 11:32 | Why Private Equity Loves CDMOs Right Now 17:59 | The Real Money-Making Formula for CDMOs 19:49 | Cell Therapy, ADCs & The Next Pharma Wave 22:58 | Tariffs, China & The New Pharma Supply Chain 25:34 | Why Most Drug Molecules Fail 30:32 | The Future of Asian CDMOs & Global Pharma 37:24 | Nick Wigdahl’s Biggest Lessons From Roche & Pharmagro ABOUT NICK WIGDAHL Prior to setting up Pharmagro, Nick managed the CHF12bn Established Products portfolio at Roche in the Pharma Technical Services division. Additional pharma experience comes from GSK. Outside of pharma he was COO for family offices in the logistics sector where he was responsible for portfolio and risk management. He studied history at Cambridge University and has a MBA from the Massachusetts Institute of Technology ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    Asia’s Growing Strength in CDMOs
  5. Apr 13

    Inside a $300M Biotech Fundraising Journey

    I thought biotech was about breakthroughs—until I realised it’s really about surviving the funding game. In this episode, I sit down with Kiran Asarpota, a biotech operator who’s lived the full cycle—from raising $300M and taking a company public on Nasdaq to navigating the brutal reality of shutdowns. We get into what biotech startups don’t tell you—why early-stage funding is drying up, what “de-risking” actually means, and how investors really think about biotech valuation and clinical data. Kiran breaks down biotech fundraising strategies, venture capital in healthcare, and what it takes to build (and lose) a company in this high-risk industry. If you're a founder, investor, or just curious about how biotech startups raise capital and scale globally—this one’s real, raw, and worth your time. References: https://www.a-star.edu.sg/News/astarNews/news/features/forget-chasing-the-next-pfizer--singapore-s-biotech-future-lies-in-innovation--not-giants  https://www.bain.com/insights/empowering-biotech-innovation-in-asia-pacific/    IN THIS EPISODE 00:00 | Why Biotech Funding Is Getting Tougher 01:53 | What “De-Risking” Really Means for Your Startup 05:29 | Fundraising Advice Every Biotech Founder Needs 06:14 | Capital Basics: Equity, Debt, What to Choose 08:07 | When Venture Debt Actually Makes Sense 11:01 | Inside a $300M Biotech Fundraising Journey 12:14 | Convertible Notes & Extending Your Runway 14:15 | Why Taiwan First, Then Nasdaq 15:59 | What Really Drives Biotech Valuation 22:14 | Why Singapore Is a Biotech Hub 24:39 | Singapore’s Edge for Global Biotech Startups 25:02 | The Gaps Holding Singapore Back 27:33 | Why Singapore Shouldn’t Build the Next Pfizer 30:50 | The Reality of Risk & Failure in Biotech 33:40 | Cash Burn Lessons from Aslan 37:06 | What to Do When Your Data Isn’t Great 39:32 | How to Communicate with Investors 41:19 | The Hard Truth About Drug Manufacturing 43:12 | Scaling Biotech Beyond the Lab 46:53 | Key Takeaways for Founders ABOUT KIRAN ASARPOTA Kiran Asarpota is Chief Operating Officer at Callio Therapeutics and leads all finance and operational matters of the company. With over 20 years of leadership experience across U.S. and international capital markets, biotech operations, and financial strategy, Kiran was most recently Chief Operating Officer of ASLAN Pharmaceuticals. Kiran brings deep product and market knowledge across Life Sciences, Biotech, MedTech, and HealthTech. ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    Inside a $300M Biotech Fundraising Journey
  6. Mar 30

    Backing Asia’s healthcare builders: A VC Playbook

    I thought healthcare investing was about money — turns out it’s about fixing a system that’s already cracking. In this episode, I sit down with Seemant Jauhari — from corporate beginnings to building his own healthcare fund and now Partner at Jungle Ventures — to unpack what’s really happening inside healthcare startups and venture capital in Asia. We get into why healthcare is one of the most resilient sectors, how digital health and AI are reshaping the space, and what founders get wrong about funding and scaling. Seemant breaks down how real investment theses are built — from hospitals to healthtech — and why capital continuity is the biggest hidden gap in venture capital today. If you're building or investing in healthcare startups, this is a clear, no-BS look at what actually works. IN THIS EPISODE 00:00 | Asia’s Healthcare Crisis No One’s Solving 01:38 | Why Healthcare Investing Always Wins 04:03 | The $ Gap in Asia You Can’t Ignore 07:25 | Infra vs AI: Where the Real Money Is 09:07 | How Top Funds Actually Pick Winners 12:12 | The Funding Gap Killing Startups 15:56 | Building a Portfolio That Survives 18:14 | How to Raise Capital (Without Wasting Time) 24:10 | Managing Investor Money Without Losing It 29:00 | Why Capital Alone Doesn’t Build Companies 30:00 | Hospital Economics That Actually Work 30:58 | Profit vs Patient Care: The Real Balance 34:03 | How Investors Actually Make Exits 38:29 | Why Deals Have Slowed (And What It Means) 42:30 | Operational Alpha: The Real Edge 49:08 | The Asset-Light Model That Scales Fast 53:16 | Governance Mistakes That Kill Companies 56:55 | Founder Lessons Most People Learn Too Late Seemant Jauhari | Partner | Jungle Ventures As a Partner Healthcare at Jungle Ventures, I lead the firm's investments in the healthcare sector across Southeast Asia and India. I have over 22 years of experience in venture capital, healthcare, public services, telecom, and IT, with a strong track record of creating, scaling, and operationalizing new businesses and nurturing them until they are on a growth trajectory. My core competencies include venture investments, business development, strategy, and healthcare innovation. I am passionate about building long-lasting businesses that solve real problems and create positive impact. I have held several board positions at healthcare startups. I hold an MBA from the Indian School of Business, a certificate from the Haas School of Business, and an executive education from Tel Aviv University. ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    Backing Asia’s healthcare builders: A VC Playbook
  7. Mar 23

    Fundraising for HealthTech in 2026: What Founders Must Do Differently

    In this episode of HealthAlpha, host Sushaant sits down with Shi-Ying Lau, Managing Partner at Adaptive Capital, to unpack how healthcare investors really think and what founders need to know to raise smarter capital in 2026 and beyond. We go deep into AI-powered diagnostics, early cancer detection, the bias in women’s health investment, and wearable health tech, and explore how Asia-based startups can successfully scale into the US market. If you’re building or investing in healthtech, medtech, biotech, or AI diagnostics, this episode is packed with real-world insights. IN THIS EPISODE 00:00 | Why Healthcare Investing Is a Team Sport 01:14 | Adaptive Capital’s Investment Thesis: AI, Diagnostics & Preventive Care 04:15 | Early Detection of Ovarian Cancer: The AOAD Diagnostics Story 10:23 | Why Women’s Health Has Been Underfunded (And Where the Real Opportunity Is) 13:53 | Blood-Based Lung Cancer Screening: Delphi Diagnostics Explained 18:52 | Clinical-Grade Wearables: How Respory Stands Out in a Crowded Market 22:54 | How VCs Evaluate HealthTech Startups 25:00 | Technical Due Diligence in Deep Tech Healthcare 26:41 | What Investors Look for in Clinical Evidence & IP Strategy 28:11 | Asian Companies Expanding to US Market 31:21 | How to Evaluate IP: Patents, Licensing & Freedom to Operate 33:37 | Reimbursement Strategy: Who Pays and Why It Matters 36:32 | Fundraising in 2026: What Founders Must Do Differently 39:37 | Building the Right Cap Table: Syndicates vs Single Lead Investors 41:17 | Hard Truths for HealthTech Founders 44:50 | What Global Investors Get Wrong About Asia 45:28 | Final Advice: Building Companies That Actually Last ABOUT SHI-YING LAU Shi-Ying  Lau | Investor | Entrepreneur | Operator |  Shi-Ying Lau is an operator and investor with 17 years of experience scaling businesses across 8 industries and 5 countries. They’ve held roles across Silicon Valley tech, corporate leadership, and management consulting. Lau has helped build the GrabCar business in Malaysia at Grab, scaling it into one of the company’s fastest-growing verticals in under two years despite intense competition and regulatory complexity. Today, Lau mentors and invests in Seed to Series C startups across the US, UK, and Southeast Asia in AI, SaaS, Healthtech, and Marketplaces — bringing a hands-on, values-driven approach to building companies. Connect with Shi-Ying Lau: https://www.linkedin.com/in/shiyinglau/   ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    Fundraising for HealthTech in 2026: What Founders Must Do Differently
  8. Mar 16

    How an Indian Startup Is Tackling Cancer Metastasis

    Most cancer deaths are caused by metastasis, not the primary tumor.  In this episode, Sushaant speaks with Arnab Roy Chowdhury about how his team at Metastop is tackling metastasis as a separate disease, using patient data, lab models, and machine learning to understand why cancer spreads and how to stop it. Their research points to cancer cell adaptation as the key bottleneck in metastasis. The team is now advancing two strategies: Drug repurposing with safe, existing medicines to delay metastasis First-in-class drug discovery targeting novel biological pathways With regulatory approval in India to begin Phase 2 trials, this approach could reshape how cancer is treated. Shifting care from reacting to metastasis to preventing it before it starts. IN THIS EPISODE 00:00 – Cancer Treatment Needs a Reset 01:24 – Metastasis 101: Why Cancer Spreads 04:50 – What Science Still Gets Wrong About Metastasis 06:16 – The Three Stages of Metastasis 12:15 – Bedside to Bench: Using Real Patient Tumors 19:52 – Why Most Anti-Metastatic Drugs Failed 22:48 – Finding the Right Targets in Cancer Spread 26:01 – From Biology to Drug Candidates 27:06 – Screening Drugs with AI + Biology 27:52 – Why Metastasis Research Is So Slow 28:49 – Drug Repurposing: The Shortcut to Patients 30:53 – Fast-Track Animal Models for Metastasis 31:54 – Real-World Evidence from Patient Histories 37:45 – Predicting Who Will Develop Metastasis 41:33 – Pharma Partnerships & Licensing Strategy 43:59 – If Metastasis Is Prevented, What Happens to the $8B Market? 45:38 – Building a Biotech Startup in India 47:35 – The Future of Cancer Care ABOUT DR. ARNAB ROY CHOWDHURY Dr. Arnab  Roy Chowdhury | Founding Director & CSO | Mestastop As the founder of Mestastop Solutions, Arnab is passionate about solving the unmet medical need of cancer metastasis, which accounts for 90% of cancer deaths. With 23 years of experience in applied therapeutics, he has led eight discovery programs, four in cancer biology, and delivered a pre-IND candidate for triple-negative breast cancer. Arnab's mission is to develop novel platforms and predictive diagnostics to identify and target the rate-limiting steps of metastasis. Mestastop has built three platforms, METAssay®, METSCAN®, and METVivo®, that fill the gaps in drug discovery and validation. Retrospective clinical studies have demonstrated the potential of the drug repurposing platform METGuard®. Prospective clinical studies are ongoing to develop companion diagnostics to identify primary tumour patients at higher metastasis risk. Arnab & Mestastop is driven by the desire to make a difference in the lives of cancer patients and their families. Connect with Arnab:  https://www.linkedin.com/in/arnabroyc/  https://mestastop.com/   https://www.nature.com/articles/s41392-025-02148-4 https://pubmed.ncbi.nlm.nih.gov/36354098/ https://www.nature.com/articles/d41586-025-04149-3 ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    How an Indian Startup Is Tackling Cancer Metastasis
  9. Mar 9

    Why Your Health Insurance Premium Keeps Rising

    In this episode of HealthAlpha, Sushaant interviews Dr. Ramesh Rajentheran to discuss the factors driving rising medical costs in Southeast Asia, challenges within health insurance companies, and ongoing difficulties patients face with claims and reimbursements. The discussion also addresses the role of regulation and brokers, the potential for AI to streamline administrative tasks, and the feasibility of integrated care models such as Kaiser Permanente in Asia. With real-world examples from Singapore, Malaysia, and Hong Kong, plus reflections for founders and investors building in healthcare, this episode is a candid, practical look at what’s broken in healthcare financing and where real change might come from. IN THIS EPISODE 01:29 | Asia’s Healthcare System Is Breaking But Why? 03:00 | Healthcare Will Decide Elections in Asia  05:02 | Asia’s Real Healthcare Crisis Is Not Hospitals 06:51 | Why Your Insurance Premium Just Exploded Overnight 09:32 | Your Insurance Company Is Wasting Your Money  16:10 | Why Health Insurance Is “Broken by Design” 23:19 | The Personal Tragedy That Sparked a Health Tech Startup 25:53 | The Data Insurers Don’t Collect (And Why That’s Insane) 26:16 | Mistake That Almost Killed the Company 26:49 | Why Health Insurance Will Never Have a “Big Disruption Moment” 27:47 | Fax Machines in 2025?! Inside the Absurd Reality of Insurance Claims 29:08 | AI Won’t Cure First. It Will Kill Paperwork  31:27 | Why Insurers Refuse to Cover the Elderly and Cancer Survivors 35:42 | This Healthcare Model Aligns Incentives (And Actually Works) 41:20 | What Governments Get Wrong About Fixing Healthcare 44:30 | Brutally Honest Startup Advice for Founders in Their 30s, 40s, and 50s ABOUT DR. RAMESH RAJENTHERAN Ramesh is CFO and Head of Asia at Cuezen, which is a leader in AI-driven health personalization. He is also an Operating partner at TVM Capital Healthcare, a private Equity fund focused on the Middle East and SEA. Ramesh is also a Founding Shareholder of Hisential, which creates high-end clinics and luxury products for men in Singapore and Malaysia.  He was formerly CEO & Co-Founder of MiyaHealth, a Strategic and VC-backed Insurance/Health technology firm that used AI to improve Health Insurance and patient experience in Asia and Europe.  Prior to this, Ramesh was CFO and COO at a Healthcare Major where he helped acquire and integrate over 20 companies in 2.5 years, creating one of Asia’s largest Managed Care and Primary Care Companies. He also executed Asia’s first guaranteed bond and the region’s first perpetual bond by a healthcare company. https://www.linkedin.com/in/ramesh-rajentheran-723248/   ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region. Patient voices: experiences of healthcare access in Asia report: https://impact.economist.com/health/patient-voices-asia  Beyond Coverage - The Social and Economic Impact of Insurance in ASEAN report: https://www.prudentialplc.com/content/dam/prudential-plc/newsroom/though-leadership/beyond-coverage-the-social-and-economic-impact-of-insurance-in-asean/beyond-coverage-report.pdf   FOMCA: People Are Taking Loans To Pay Medical Insurance: https://www.youtube.com/watch?v=bHlSOBgxE3w  #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare

    Why Your Health Insurance Premium Keeps Rising
  10. Feb 27

    Why India Isn’t Ready for Its Aging Population

    In the debut episode of Health Alpha, host Sushaant sits down with Jyothish, the founder of LivEzee, to discuss one of the most pressing demographic shifts of our time: the "super-aging" of Asia. While the world focuses on youth, a silent revolution is happening in countries like India, where the elderly population is expected to grow by 134% over the next three decades. Nowhere is this more evident than in Kerala, where migration and changing family structures have left many seniors living alone. We dive deep into how technology, from AI-driven health predictions to IoT fall sensors, is being used to help seniors live happily, healthily, and independently in their own homes. IN THIS EPISODE 00:58 | From Investment Banking to Elder Care. Jyothish’s Personal Journey 05:54 | Why Is Kerala Aging Faster Than the Rest of India 10:30 | How Migration Reshaped Kerala’s Economy 18:58 | How Kerala’s Elders Live, Spend, and Worry About the Future 22:34 | Rethinking Elder Care: Why LivEzee Was Built 26:59 | The 3H Model Explained: Health, Happiness and Home 36:17 | AI, IoT, and Prevention: How Tech Is Powering Elder Care at Home 46:43 | Aging Is Not “Them”: Dignity, Independence, and Our Future Selves ABOUT JYOTHISH PARAMESWARAN MOHINI (PM) Jyothish Parameswaran Mohini is the Co Founder and CEO of LivEzee | Elder Care Solutions. At the helm of LivEzee Eldercare, his focus lies in revolutionizing eldercare through the synthesis of AI and personalized human attention, ensuring the safety and well-being of seniors. This mission leverages his expertise in orchestrating strategic growth, business development and innovation, skills honed while leading various strategic endeavors in the financial services industry in Asia-Pacific through the last 2 decades. Connect with Jyothish: https://www.linkedin.com/in/pmjyothish/  Find the INDIA AGEING REPORT 2023 here: https://india.unfpa.org/en/publications/caring-our-elders-institutional-responses-india-ageing-report-2023  ABOUT SUSHAANT BAKHRU Sushaant Bakhru is an experienced healthcare professional with 15+ years in the industry, covering consulting, investment banking and corporate strategy / M&A. He is based in Singapore and is an advisor to healthcare startups and PE funds in the region.  Connect with Sushaant: https://www.linkedin.com/in/sbakhru/  ABOUT HealthAlpha  HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories and people behind them. Through weekly conversations with Founders and Investors across Asia, it will highlight gaps in healthcare systems, the people leveraging technology to effect disruptive change and the investors backing them. #HealthAlpha #HealthTech #HealthcareInnovation #FutureOfHealthcare #Asia

    Why India Isn’t Ready for Its Aging Population

About

HealthAlpha is a podcast aimed at the intersection of healthcare and business, showcasing innovative healthcare technologies and stories behind them. Through weekly conversations with pioneers across Asia, it will highlight gaps in healthcare systems and the people leveraging technology to effect disruptive change in the region.